Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)

This grant, titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)," embraces research focused on the development of unique approaches to screen and/or treat potentially fatal or disabling conditions that could be identified in newborns. This includes particular genetic conditions that could feasibly be screened for in the near future and have been given "high priority" status.

The aim for an accurate screening test is emphasized, along with the necessity of showcasing the benefits of early intervention or treatment. These factors play a crucial role in deciding whether a condition should be included on a newborn screening panel. A "high priority" condition, as defined by this grant, refers to one that is not currently recommended for screening, yet infants with this condition could greatly benefit from early detection and subsequent treatment.